{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:56:44Z","timestamp":1785779804853,"version":"3.56.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T00:00:00Z","timestamp":1615593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009414","name":"Istituto Oncologico Veneto","doi-asserted-by":"publisher","award":["L03P07"],"award-info":[{"award-number":["L03P07"]}],"id":[{"id":"10.13039\/501100009414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009414","name":"Istituto Oncologico Veneto","doi-asserted-by":"publisher","award":["L04P11"],"award-info":[{"award-number":["L04P11"]}],"id":[{"id":"10.13039\/501100009414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009414","name":"Istituto Oncologico Veneto","doi-asserted-by":"publisher","award":["L05P07"],"award-info":[{"award-number":["L05P07"]}],"id":[{"id":"10.13039\/501100009414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell'Istruzione dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2017EKMFTN_006"],"award-info":[{"award-number":["2017EKMFTN_006"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.esmoop.2021.100099","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T06:37:15Z","timestamp":1617345435000},"page":"100099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study"],"prefix":"10.1016","volume":"6","author":[{"given":"F.","family":"Schettini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Buono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"De Placido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Parola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Griguolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bighin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cianniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"De Laurentiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pelizzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bonotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Frassoldati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Montemurro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cognetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Locci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Generali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"De Placido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Arpino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2021.100099_bib1","doi-asserted-by":"crossref","first-page":"101965","DOI":"10.1016\/j.ctrv.2020.101965","article-title":"HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis","volume":"84","author":"Schettini","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100099_bib2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100099_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2018.03.015","article-title":"Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort","volume":"96","author":"Gobbini","year":"2018","journal-title":"Eur J Cancer"},{"issue":"19","key":"10.1016\/j.esmoop.2021.100099_bib4","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100099_bib5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100099_bib6","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/annonc\/mdz061","article-title":"Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)","volume":"30","author":"Bachelot","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100099_bib7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100099_bib8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2021.100099_bib9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.breast.2017.12.012","article-title":"Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results","volume":"38","author":"De Placido","year":"2018","journal-title":"Breast"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2021.100099_bib10","article-title":"Abstract P1-18-14: Use of pertuzumab in combination with taxanes for HER2-positive metastatic breast cancer (MBC): analysis of US electronic health records","volume":"80","author":"Polito","year":"2020","journal-title":"Cancer Res"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2021.100099_bib11","doi-asserted-by":"crossref","first-page":"e12504","DOI":"10.1200\/JCO.2017.35.15_suppl.e12504","article-title":"Efficacy of pertuzumab in combination with trastuzumab and a taxane in first-line treatment for metastatic breast cancer (MBC): a multicenter, retrospective, observational study","volume":"35","author":"Gamucci","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100099_bib12","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Di\u00e9ras","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100099_bib13","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100099_bib14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100099_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-019-05284-y","article-title":"Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial","volume":"177","author":"Lambertini","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100099_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/GCO.0b013e3283414e87","article-title":"HER2-positive breast cancer: current management of early, advanced, and recurrent disease","volume":"23","author":"Callahan","year":"2011","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100099_bib17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.clon.2013.11.028","article-title":"Clinical outcome of HER2-positive breast cancer patients after failure on adjuvant trastuzumab: the potential of the time to relapse","volume":"26","author":"Di Cosimo","year":"2014","journal-title":"Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100099_bib18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.clon.2013.08.011","article-title":"Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial","volume":"26","author":"L\u00e1ng","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.esmoop.2021.100099_bib19","doi-asserted-by":"crossref","first-page":"e000979","DOI":"10.1136\/esmoopen-2020-000979","article-title":"Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial","volume":"5","author":"Lambertini","year":"2020","journal-title":"ESMO Open"},{"issue":"26","key":"10.1016\/j.esmoop.2021.100099_bib20","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1200\/JCO.2018.79.2697","article-title":"Systemic therapy for patients with advanced human epidermal growth factor receptor 2\u2013positive breast cancer: ASCO clinical practice guideline update","volume":"36","author":"Giordano","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"38","key":"10.1016\/j.esmoop.2021.100099_bib21","doi-asserted-by":"crossref","first-page":"64481","DOI":"10.18632\/oncotarget.16373","article-title":"Efficacy and safety of T-DM1 in the \u201ccommon-practice\u201d of HER2+ advanced breast cancer setting: a multicenter study","volume":"8","author":"Fabi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2021.100099_bib22","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.3390\/cancers12071902","article-title":"ERBB2 mRNA expression and response to ado-trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"12","author":"Griguolo","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100099_bib23","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1016\/j.clbc.2019.09.001","article-title":"T-DM1 efficacy in patients with HER2-positive metastatic breast cancer progressing after a taxane plus pertuzumab and trastuzumab: an Italian multicenter observational study","volume":"20","author":"Conte","year":"2020","journal-title":"Clin Breast Cancer"},{"issue":"16","key":"10.1016\/j.esmoop.2021.100099_bib24","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2021.100099_bib25","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"31","key":"10.1016\/j.esmoop.2021.100099_bib26","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100099_bib27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100099_bib28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","article-title":"Partial residuals for the proportional hazards regression model","volume":"69","author":"Schoenfeld","year":"1982","journal-title":"Biometrika"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100099_bib29","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s12282-020-01057-4","article-title":"Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01","volume":"27","author":"Yamashiro","year":"2020","journal-title":"Breast Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100099_bib30","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"35","key":"10.1016\/j.esmoop.2021.100099_bib31","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.19.00443","article-title":"Incidence of late relapses in patients with HER2-positive breast cancer receiving adjuvant trastuzumab: combined analysis of NCCTG N9831 (Alliance) and NRG oncology\/NSABP B-31","volume":"37","author":"Chumsri","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100099_bib32","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00432-015-2033-z","article-title":"Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study","volume":"142","author":"Arpino","year":"2016","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100099_bib33","unstructured":"US Food and Drug Administration. Highlights of Prescribing Information for T-DM1. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125427s105lbl.pdf. Accessed December 31, 2020."},{"key":"10.1016\/j.esmoop.2021.100099_bib34","series-title":"Summary of Product Characteristics of T-DM1","year":"2021"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100099_bib35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","article-title":"Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2\u2013positive, advanced breast cancer: primary results from the phase III MARIANNE study","volume":"35","author":"Perez","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100099_bib36","doi-asserted-by":"crossref","first-page":"iii57","DOI":"10.1093\/annonc\/mdz100.028","article-title":"Pertuzumab (P) as \u2265 second-line therapy for HER2-positive metastatic breast cancer (mBC): Swiss clinical experience","volume":"30","author":"Biskup","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100099_bib37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10549-016-3851-7","article-title":"Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study","volume":"158","author":"Smyth","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100099_bib38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/ajco.13195","article-title":"Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: an Australian case series","volume":"15","author":"Bergin","year":"2019","journal-title":"Asia Pac J Clin Oncol"},{"issue":"26","key":"10.1016\/j.esmoop.2021.100099_bib39","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1200\/JCO.2016.70.6267","article-title":"Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy","volume":"35","author":"Urruticoechea","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2021.100099_bib40","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.18632\/oncotarget.27603","article-title":"Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting","volume":"11","author":"Del Prete","year":"2020","journal-title":"Oncotarget"},{"issue":"34","key":"10.1016\/j.esmoop.2021.100099_bib41","doi-asserted-by":"crossref","first-page":"56921","DOI":"10.18632\/oncotarget.18176","article-title":"A\u00a0retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience","volume":"8","author":"Vici","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2021.100099_bib42","first-page":"100188","article-title":"Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience","volume":"24","author":"Battisti","year":"2020","journal-title":"Cancer Treat Res Commun"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100099_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100099_bib44","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100099_bib45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2021.100099_bib46","unstructured":"US Food and Drug Administration. Highlights of Prescribing Information for Pertuzumab. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125409s051lbl.pdf. Accessed December 31, 2020."},{"key":"10.1016\/j.esmoop.2021.100099_bib47","series-title":"Summary of Product Characteristics of Pertuzumab","year":"2021"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100099_bib48","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100099_bib49","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.7932","article-title":"Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial","author":"Rugo","year":"2021","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100099_bib50","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921000569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921000569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:26:46Z","timestamp":1761856006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921000569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2059702921000569"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100099","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100099"}}